Precision Wealth Strategies’s Intellia Therapeutics NTLA Stock Holding History

Precision Wealth Strategies’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,174	Closed	-$885K	–	174
2022 Q1	$885K	Buy	12,174 +2,694	+28%	+$228K	0.53%	36
2021 Q4	$1.12M	Buy	9,480 +37	+0.4%	+$4.63K	0.81%	24
2021 Q3	$1.27M	Buy	9,443 +1,450	+18%	+$220K	0.98%	16
2021 Q2	$1.29M	Buy	7,993 +585	+8%	+$45.6K	1.11%	18
2021 Q1	$595K	Buy	7,408 +1,427	+24%	+$95.8K	0.57%	23
2020 Q4	$325K	Buy	+5,981	New	+$217K	0.35%	36

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Precision Wealth Strategies's NTLA Position: Q2 2022 in Review

Precision Wealth Strategies sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 12,174 shares — an estimated $885K sold.

Precision Wealth Strategies first reported a position in NTLA in Q4 2020 and held it in 6 quarters. The position peaked at $1.29M in Q2 2021. 300 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

Precision Wealth Strategies reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
Precision Wealth Strategies sold 12,174 Intellia Therapeutics shares in Q2 2022, an estimated $885K.
Precision Wealth Strategies first reported a position in Intellia Therapeutics in Q4 2020 and held it in 6 quarters.
Precision Wealth Strategies's Intellia Therapeutics position peaked at $1.29M in Q2 2021.
300 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on Precision Wealth Strategies's 13F filing for Q2 2022, filed 14 Jul 2022.